Core Insights - Kymera Therapeutics missed Q4 revenue and EPS estimates, reporting $2.87 million in revenue against an expected $17.30 million and an EPS of -$0.97 compared to the -$0.79 estimate, while holding $1.62 billion in cash [1] - The company announced the first IRF5-directed therapy in human history, KT-579, which targets multiple autoimmune conditions, with Phase 1 data expected in the second half of 2026 [1] - Kymera's lead drug, KT-621, is positioned as an oral alternative to Regeneron's dupilumab, targeting a $20 billion market with significant unmet needs among Type 2 patients [1] Financial Performance - Kymera reported a full-year net loss of $311.35 million, with R&D spending of $83.83 million in Q4 [1] - The company completed a $692 million equity offering in December 2025, providing a cash runway into 2029 [1] - Analyst consensus rates the stock as "Buy," with a 12-month price target ranging from $117.60 to $123.41, while the stock trades around $83.49 [1] Clinical Developments - KT-621 is currently in two Phase 2b trials, with data expected from BROADEN2 in mid-2027 and BREADTH in late 2027 [1] - The Phase 1b data for KT-621 showed results comparable to dupilumab across all clinical endpoints evaluated in atopic dermatitis patients [1] - KT-579 represents a novel approach to treating autoimmune diseases, with no prior successful clinical targeting of the IRF5 mechanism [1]